Developer docs
API playgroundTry for free, no card

Search company profiles

Deep Bio

Full company profile

uuid0000s6j

Namestring
Deep Bio
Legal namestring
주식회사 딥바이오 (Deep Bio Inc.)
Websiteurl
deepbio.co.kr
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Deep Bio is a Seoul, South Korea-based medical AI company founded in 2015 that develops deep learning software for digital pathology, with a primary focus on cancer detection, grading, and quantification in prostate and breast tissue specimens. Its core product suite, branded DeepDx, analyzes H&E-stained and IHC-stained whole-slide images to detect cancer, assign Gleason scores, quantify tumor area, and (in newer modules) predict recurrence risk. The underlying technology includes the proprietary YAAGGS weakly-supervised learning model, which reduces dependence on region-level manual annotations and supports generalization across varying staining protocols. The portfolio includes DeepDx Prostate for core needle biopsy, radical prostatectomy, and TURP specimens; DeepDx Breast for resection and sentinel lymph node biopsy; and DeepCDx Membrane IHC for immunohistochemistry analysis.

The company's go-to-market operates through three channels: direct enterprise sales to Korean public hospitals via the Public Procurement Service (where DeepDx Prostate Pro holds Innovative Product designation), distribution partnerships with global digital pathology platform vendors (Roche navify, PathAI AISight, Visiopharm, Indica Labs HALO AP, Gestalt PathFlow, Tribun Health CaloPix, Lumea) for international reach, and research collaborations with academic medical centers including Stanford Medicine, ARUP Laboratories, Dana-Farber Cancer Institute, and Seoul National University Hospital. Revenue is generated via B2B licensing and subscription arrangements with hospitals, pathology labs, and platform integrators; pricing is not publicly disclosed and is negotiated on a quote basis. The company achieved MFDS Class III approval in November 2021 — the first AI cancer diagnostic support software to do so in Korea — and holds MDSAP, ISO 13485, ISO 27001, ISO 27701, and KGMP certifications, providing regulatory access to the US, Canada, Japan, Australia, and Brazil.

As of early 2026 the company was operating with a reduced team of approximately nine employees (down from roughly 30), pursuing a small bridge financing round, and relying on its platform-vendor distribution partners to penetrate the US hospital market. Product investment and partnership activity remain active, with the most recent launches including DeepCDx Membrane IHC (May 2025), a prognostic AI algorithm for prostate cancer (April 2025), and a breast cancer recurrence risk model (October 2025).

Short descriptiontext

Deep Bio is a Seoul-based medical AI company developing deep learning software for digital pathology, primarily for prostate and breast cancer detection and grading on whole-slide images, sold to hospitals and pathology labs via licensing and integration with major digital pathology platforms including Roche and PathAI.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology AI, cancer diagnostic software, whole-slide image analysis, prostate cancer detection, breast cancer diagnostics
Industry5 codes
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
NAICS code3 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers5132
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Digital Pathology AI Diagnostics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1AI Diagnostic Software Licensing
TypeSubscription Recurring
Description

B2B licensing of DeepDx Prostate AI diagnostic software to hospitals, pathology labs, and digital pathology platform providers. Software analyzed over 500k cores at US CLIA labs as of June 2021, indicating commercial usage and testing volume.

deepbio.co.kr
2Enterprise Software Sales
TypeOne Time License
Description

Direct enterprise sales to hospitals for clinical use, with active pipeline including U.S. hospital deals in contracting stage.

koreabiomed.com
3Platform Integration Licensing
TypeLicensing Royalties
Description

Licensing arrangements with digital pathology platform vendors (Roche navify, PathAI AISight, Visiopharm, Indica Labs HALO) for integration of AI algorithms into their platforms.

deepbio.co.kr
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels9 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details1 tier
1Enterprise licensing for hospitals and pathology labs
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing for clinical deployment; negotiated through distribution partnerships with platform vendors

koreabiomed.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1DeepDx
Description

AI-powered diagnostic software suite for cancer detection and analysis

deepbio.co.kr
+4 more records
Core offering1 text field

Deep Bio develops and sells AI-powered digital pathology software (the DeepDx suite) that analyzes whole-slide images of H&E-stained and IHC-stained tissue specimens to detect, grade, and quantify cancer. The software targets prostate cancer (core needle biopsy, radical prostatectomy, TURP specimens) and breast cancer (resection, sentinel lymph node biopsy), and is licensed to hospitals, pathology labs, and integrated into major digital pathology platforms including Roche navify, PathAI AISight, Visiopharm, Indica Labs HALO AP, Gestalt PathFlow, and Tribun Health CaloPix.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 99% sensitivity and 94% specificity in clinical validation study
+4 more records
Product overview1 text field

Deep Bio offers DeepDx, a unified suite of AI-powered cancer diagnostic solutions for digital pathology. The portfolio includes specialized products for prostate cancer analysis across three specimen types — DeepDx Prostate for core needle biopsy (CNB), radical prostatectomy (RP), and transurethral resection of the prostate (TURP) — and breast cancer analysis for resection specimens and sentinel lymph node biopsy (SLNB). All products analyze digitized whole-slide tissue images using proprietary deep learning algorithms to detect cancer, grade severity, and quantify tumor metrics. The suite is anchored by the DeepDx Viewer for image visualization. The products share a common AI technology platform, with models trained on H&E-stained and IHC-stained specimens, and are integrated into multiple third-party digital pathology platforms (PathAI AISight, Visiopharm, Indica Labs HALO AP, Gestalt PathFlow, Tribun Health CaloPix) for broad market access.

Product and service6 records
1DeepDx Viewer
CategoryDigital Pathology Software
Description

A general-purpose digital pathology image viewer for viewing and interacting with digitized whole-slide tissue specimens. Serves as the visualization layer for the DeepDx AI suite.

2DeepDx Prostate – CNB (Core Needle Biopsy)
CategoryCancer Diagnostic Software
Description

AI-powered prostate cancer diagnostic support software for core needle biopsy specimens. Analyzes H&E-stained whole-slide images to automatically detect prostate cancer, assign Gleason scores and grade groups, and quantify tumor area. MFDS-approved Class III medical device.

3DeepDx Prostate – RP (Radical Prostatectomy)
CategoryCancer Diagnostic Software
Description

AI analysis solution for prostate cancer detection and grading on radical prostatectomy (RP) whole-mount specimens. Extends DeepDx Prostate capabilities from biopsy to surgical resection specimens.

4DeepDx Prostate – TURP
CategoryCancer Diagnostic Software
Description

AI software that detects prostate cancer in specimens collected via transurethral resection of the prostate (TURP), performed on patients with benign prostatic hyperplasia. Enables cancer detection beyond standard biopsies.

5DeepDx Breast – Resection
CategoryCancer Diagnostic Software
Description

AI-powered breast cancer diagnostic solution for resection tissue specimens. Differentiates breast cancer lesions accurately using deep learning algorithms for surgical resection samples.

6DeepDx Breast – SLNB (Sentinel Lymph Node Biopsy)
CategoryCancer Diagnostic Software
Description

AI solution for detecting breast cancer metastasis in sentinel lymph node biopsy (SLNB) specimens. Supports breast cancer staging by analyzing lymph node tissue for metastatic spread during surgical management.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-11-19
Description

PathAI announced integration of Deep Bio's prostate cancer analysis solution (DeepDx Prostate) into its AISight Image Management System, combining AI tools for prostate, breast, and lung cancer diagnostics to improve pathology workflows.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-09-09
Description

Deep Bio announced collaboration with Roche to integrate its advanced suite of AI algorithms into the navify Digital Pathology enterprise software, enabling broader market access through Roche's established hospital relationships.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-09-05
Description

MOU signed to advance AI-driven companion diagnostics and clinical trials, leveraging cutting-edge AI technologies for biomarker discovery in life sciences sector.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-11-15
Description

Collaborative integration of clinical-grade AI prostate cancer grading solution with Visiopharm's leading digital pathology platform, providing pathologists access to state-of-the-art AI prostate cancer analysis.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-10-31
Description

Deep Bio successfully integrated DeepDx Prostate algorithm into the HALO AP platform from Indica Labs, enabling high throughput diagnostic process for pathologists.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-11-30
Description

Collaboration agreement with Paris-based Tribun Health to integrate DeepDx Prostate into their CaloPix platform for AI-powered digital pathology, strengthening presence in Europe and Canada.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2021-07-22
Description

Renewed research collaboration as part of MADCaP Consortium to evaluate DeepDx Prostate for prostate cancer tumor analysis across Sub-Saharan Africa centers, led by Dr. Timothy Rebbeck.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2021-07-16
Description

Extended software license agreement for DeepDx Prostate to be used in Stanford research study on radical prostatectomy specimens, evaluating AI performance against researcher diagnosis data.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2021-07-16
Description

Research collaboration to evaluate whether applying DeepDx Prostate in ARUP's pathology workflow can lead to higher diagnostic performance compared to microscope-based diagnosis.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2021-07-14
Description

Strategic relationship for development of integrated workflow allowing pathologists to use AI algorithms directly within Gestalt's PathFlow platform for prostate cancer diagnosis.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-03-01
Description

Commercial partnership with US-based digital pathology solution company Lumea for distribution of DeepDx Prostate products and commercial rights for image use.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Collaborative research partner for multiple studies including c-MET expression analysis and various cancer diagnostic research projects.

13Hanyang University Medical Center
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Provided specimens (7,600 H&E-stained prostate core needle biopsy samples) for YAAGGS study training and validation.

deepbio.co.kr
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

India-based AI pathology company offering deep-learning solutions for cancer detection in digital pathology; comparable in scope and customer type to Deep Bio's product suite.

TypeDirect peer
Description

Direct AI pathology competitor offering FDA-authorized AI cancer detection products for prostate and breast; competes for the same hospital and reference-lab customers with overlapping product surface.

TypeDirect peer
Description

AI pathology vendor with clinically deployed prostate and breast cancer detection products; directly comparable to DeepDx Prostate in customer use cases and clinical settings.

TypeDirect peer
Description

Both partner and competitor: PathAI's AISight hosts Deep Bio's prostate AI but also develops its own cancer detection algorithms, making it the closest peer in technology stack and target customer.

TypeDirect peer
Description

AI pathology and biomarker discovery platform targeting pharma and clinical customers with deep-learning cancer diagnostics; overlaps with Deep Bio on AI pathology and emerging companion-diagnostic ambitions.

TypeDirect peer
Description

Digital pathology platform that competes with the same DeepDx-style AI workflow positioning; Proscia's Concentriq platform is an alternative integration channel to PathAI/Roche navify.

TypeRegional player
Description

Korean AI medical imaging company with Lunit INSIGHT for mammography and pathology-adjacent products; comparable as a Korean peer pursuing AI in oncology diagnostics with global commercial ambitions.

TypeBroad incumbent
Description

Large incumbent enterprise pathology platform that both hosts Deep Bio's AI and competes for AI workflow dollars; comparable as the dominant platform-level player shaping go-to-market.

TypeBroad incumbent
Description

Large incumbent with IntelliSite digital pathology platform and AI partnerships; comparable as an established pathology vendor competing for the same hospital budgets.

TypeOthers
Description

Digital pathology platform partner that distributes Deep Bio's prostate AI; relevant because platform-vendor economics determine Deep Bio's channel access in clinical workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Deep Bio

Digital Pathology AI Diagnosticsdeepbio.co.kr

Deep Bio is a Seoul-based medical AI company developing deep learning software for digital pathology, primarily for prostate and breast cancer detection and grading on whole-slide images, sold to hospitals and pathology labs via licensing and integration with major digital pathology platforms including Roche and PathAI.

What Deep Bio does

Deep Bio is a Seoul, South Korea-based medical AI company founded in 2015 that develops deep learning software for digital pathology, with a primary focus on cancer detection, grading, and quantification in prostate and breast tissue specimens. Its core product suite, branded DeepDx, analyzes H&E-stained and IHC-stained whole-slide images to detect cancer, assign Gleason scores, quantify tumor area, and (in newer modules) predict recurrence risk. The underlying technology includes the proprietary YAAGGS weakly-supervised learning model, which reduces dependence on region-level manual annotations and supports generalization across varying staining protocols. The portfolio includes DeepDx Prostate for core needle biopsy, radical prostatectomy, and TURP specimens; DeepDx Breast for resection and sentinel lymph node biopsy; and DeepCDx Membrane IHC for immunohistochemistry analysis.

The company's go-to-market operates through three channels: direct enterprise sales to Korean public hospitals via the Public Procurement Service (where DeepDx Prostate Pro holds Innovative Product designation), distribution partnerships with global digital pathology platform vendors (Roche navify, PathAI AISight, Visiopharm, Indica Labs HALO AP, Gestalt PathFlow, Tribun Health CaloPix, Lumea) for international reach, and research collaborations with academic medical centers including Stanford Medicine, ARUP Laboratories, Dana-Farber Cancer Institute, and Seoul National University Hospital. Revenue is generated via B2B licensing and subscription arrangements with hospitals, pathology labs, and platform integrators; pricing is not publicly disclosed and is negotiated on a quote basis. The company achieved MFDS Class III approval in November 2021 — the first AI cancer diagnostic support software to do so in Korea — and holds MDSAP, ISO 13485, ISO 27001, ISO 27701, and KGMP certifications, providing regulatory access to the US, Canada, Japan, Australia, and Brazil.

As of early 2026 the company was operating with a reduced team of approximately nine employees (down from roughly 30), pursuing a small bridge financing round, and relying on its platform-vendor distribution partners to penetrate the US hospital market. Product investment and partnership activity remain active, with the most recent launches including DeepCDx Membrane IHC (May 2025), a prognostic AI algorithm for prostate cancer (April 2025), and a breast cancer recurrence risk model (October 2025).

Deep Bio firmographics

Firmographics
Name
Deep Bio
Legal name
주식회사 딥바이오 (Deep Bio Inc.)
Website
https://deepbio.co.kr
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Deep Bio is a Seoul-based medical AI company developing deep learning software for digital pathology, primarily for prostate and breast cancer detection and grading on whole-slide images, sold to hospitals and pathology labs via licensing and integration with major digital pathology platforms including Roche and PathAI.
Ownership category
akta.pro rank

Deep Bio industry classification

Industry
Product category
Digital Pathology AI Diagnostics
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics

Keywords

  • Digital pathology AI
  • Cancer diagnostic software
  • Whole-slide image analysis
  • Prostate cancer detection
  • Breast cancer diagnostics

Where Deep Bio is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

Deep Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. AI Diagnostic Software Licensing: B2B licensing of DeepDx Prostate AI diagnostic software to hospitals, pathology labs, and digital pathology platform providers. Software analyzed over 500k cores at US CLIA labs as of June 2021, indicating commercial usage and testing volume.
  2. Enterprise Software Sales: Direct enterprise sales to hospitals for clinical use, with active pipeline including U.S. hospital deals in contracting stage.
  3. Platform Integration Licensing: Licensing arrangements with digital pathology platform vendors (Roche navify, PathAI AISight, Visiopharm, Indica Labs HALO) for integration of AI algorithms into their platforms.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise licensing for hospitals and pathology labs

Go-to-market motion3 records

Distribution channels9 records

Marketing channels5 records

Deep Bio product offering

Product offering

Core offering

Deep Bio develops and sells AI-powered digital pathology software (the DeepDx suite) that analyzes whole-slide images of H&E-stained and IHC-stained tissue specimens to detect, grade, and quantify cancer. The software targets prostate cancer (core needle biopsy, radical prostatectomy, TURP specimens) and breast cancer (resection, sentinel lymph node biopsy), and is licensed to hospitals, pathology labs, and integrated into major digital pathology platforms including Roche navify, PathAI AISight, Visiopharm, Indica Labs HALO AP, Gestalt PathFlow, and Tribun Health CaloPix.

Product overview

Deep Bio offers DeepDx, a unified suite of AI-powered cancer diagnostic solutions for digital pathology. The portfolio includes specialized products for prostate cancer analysis across three specimen types — DeepDx Prostate for core needle biopsy (CNB), radical prostatectomy (RP), and transurethral resection of the prostate (TURP) — and breast cancer analysis for resection specimens and sentinel lymph node biopsy (SLNB). All products analyze digitized whole-slide tissue images using proprietary deep learning algorithms to detect cancer, grade severity, and quantify tumor metrics. The suite is anchored by the DeepDx Viewer for image visualization. The products share a common AI technology platform, with models trained on H&E-stained and IHC-stained specimens, and are integrated into multiple third-party digital pathology platforms (PathAI AISight, Visiopharm, Indica Labs HALO AP, Gestalt PathFlow, Tribun Health CaloPix) for broad market access.

Differentiator

Problem solved

Functional benefit

Brands

  • DeepDx: AI-powered diagnostic software suite for cancer detection and analysis
  • DeepDx Prostate
  • DeepDx Prostate Pro
  • DeepCDx Membrane IHC
  • DeepDx Breast

Products and services

  • DeepDx Viewer A general-purpose digital pathology image viewer for viewing and interacting with digitized whole-slide tissue specimens. Serves as the visualization layer for the DeepDx AI suite.
  • DeepDx Prostate – CNB (Core Needle Biopsy) AI-powered prostate cancer diagnostic support software for core needle biopsy specimens. Analyzes H&E-stained whole-slide images to automatically detect prostate cancer, assign Gleason scores and grade groups, and quantify tumor area. MFDS-approved Class III medical device.
  • DeepDx Prostate – RP (Radical Prostatectomy) AI analysis solution for prostate cancer detection and grading on radical prostatectomy (RP) whole-mount specimens. Extends DeepDx Prostate capabilities from biopsy to surgical resection specimens.
  • DeepDx Prostate – TURP AI software that detects prostate cancer in specimens collected via transurethral resection of the prostate (TURP), performed on patients with benign prostatic hyperplasia. Enables cancer detection beyond standard biopsies.
  • DeepDx Breast – Resection AI-powered breast cancer diagnostic solution for resection tissue specimens. Differentiates breast cancer lesions accurately using deep learning algorithms for surgical resection samples.
  • DeepDx Breast – SLNB (Sentinel Lymph Node Biopsy) AI solution for detecting breast cancer metastasis in sentinel lymph node biopsy (SLNB) specimens. Supports breast cancer staging by analyzing lymph node tissue for metastatic spread during surgical management.

Quantifiable outcome

  • 99% sensitivity and 94% specificity in clinical validation study
  • +4 more outcomes

Companies that use Deep Bio

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles3 records

Deep Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability4 records

Feature4 records

Deep Bio partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core, strategic and major.

  • PathAIcoreTechnology or Integration · 19 November 2024PathAI announced integration of Deep Bio's prostate cancer analysis solution (DeepDx Prostate) into its AISight Image Management System, combining AI tools for prostate, breast, and lung cancer diagnostics to improve pathology workflows.
  • Roche DiagnosticscoreTechnology or Integration · 9 September 2024Deep Bio announced collaboration with Roche to integrate its advanced suite of AI algorithms into the navify Digital Pathology enterprise software, enabling broader market access through Roche's established hospital relationships.
  • ABIONstrategicStrategic or Co-development Partner · 5 September 2024MOU signed to advance AI-driven companion diagnostics and clinical trials, leveraging cutting-edge AI technologies for biomarker discovery in life sciences sector.
  • VisiopharmcoreTechnology or Integration · 15 November 2022Collaborative integration of clinical-grade AI prostate cancer grading solution with Visiopharm's leading digital pathology platform, providing pathologists access to state-of-the-art AI prostate cancer analysis.
  • Indica LabscoreTechnology or Integration · 31 October 2022Deep Bio successfully integrated DeepDx Prostate algorithm into the HALO AP platform from Indica Labs, enabling high throughput diagnostic process for pathologists.
  • Tribun HealthcoreTechnology or Integration · 30 November 2021Collaboration agreement with Paris-based Tribun Health to integrate DeepDx Prostate into their CaloPix platform for AI-powered digital pathology, strengthening presence in Europe and Canada.
  • Dana-Farber Cancer InstitutestrategicStrategic or Co-development Partner · 22 July 2021Renewed research collaboration as part of MADCaP Consortium to evaluate DeepDx Prostate for prostate cancer tumor analysis across Sub-Saharan Africa centers, led by Dr. Timothy Rebbeck.
  • Stanford MedicinestrategicStrategic or Co-development Partner · 16 July 2021Extended software license agreement for DeepDx Prostate to be used in Stanford research study on radical prostatectomy specimens, evaluating AI performance against researcher diagnosis data.
  • ARUP LaboratoriesstrategicStrategic or Co-development Partner · 16 July 2021Research collaboration to evaluate whether applying DeepDx Prostate in ARUP's pathology workflow can lead to higher diagnostic performance compared to microscope-based diagnosis.
  • Gestalt DiagnosticsmajorTechnology or Integration · 14 July 2021Strategic relationship for development of integrated workflow allowing pathologists to use AI algorithms directly within Gestalt's PathFlow platform for prostate cancer diagnosis.
  • LumeamajorChannel Partner/ Reseller/ Distributor · 1 March 2021Commercial partnership with US-based digital pathology solution company Lumea for distribution of DeepDx Prostate products and commercial rights for image use.
  • Samsung Medical CenterstrategicStrategic or Co-development PartnerCollaborative research partner for multiple studies including c-MET expression analysis and various cancer diagnostic research projects.
  • Hanyang University Medical CenterstrategicStrategic or Co-development PartnerProvided specimens (7,600 H&E-stained prostate core needle biopsy samples) for YAAGGS study training and validation.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Deep Bio competitors and assessment

Company assessment

Direct peers

  • AIRA Matrix: India-based AI pathology company offering deep-learning solutions for cancer detection in digital pathology; comparable in scope and customer type to Deep Bio's product suite.
  • Paige.AI: Direct AI pathology competitor offering FDA-authorized AI cancer detection products for prostate and breast; competes for the same hospital and reference-lab customers with overlapping product surface.
  • Ibex Medical Analytics: AI pathology vendor with clinically deployed prostate and breast cancer detection products; directly comparable to DeepDx Prostate in customer use cases and clinical settings.
  • PathAI: Both partner and competitor: PathAI's AISight hosts Deep Bio's prostate AI but also develops its own cancer detection algorithms, making it the closest peer in technology stack and target customer.
  • Owkin: AI pathology and biomarker discovery platform targeting pharma and clinical customers with deep-learning cancer diagnostics; overlaps with Deep Bio on AI pathology and emerging companion-diagnostic ambitions.
  • Proscia: Digital pathology platform that competes with the same DeepDx-style AI workflow positioning; Proscia's Concentriq platform is an alternative integration channel to PathAI/Roche navify.

Regional players

  • Lunit: Korean AI medical imaging company with Lunit INSIGHT for mammography and pathology-adjacent products; comparable as a Korean peer pursuing AI in oncology diagnostics with global commercial ambitions.

Broad incumbents

  • Roche (navify Digital Pathology): Large incumbent enterprise pathology platform that both hosts Deep Bio's AI and competes for AI workflow dollars; comparable as the dominant platform-level player shaping go-to-market.
  • Philips Digital Pathology: Large incumbent with IntelliSite digital pathology platform and AI partnerships; comparable as an established pathology vendor competing for the same hospital budgets.

Others

  • Visiopharm: Digital pathology platform partner that distributes Deep Bio's prostate AI; relevant because platform-vendor economics determine Deep Bio's channel access in clinical workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Deep Bio social profiles

Digital presence

Deep Bio compliance and trust

Trust signal

Compliance6 records

Deep Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Deep Bio leadership team

Management profile

Number of profiles

Profiles5 records

Deep Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Deep Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deep Bio

What does Deep Bio do?

Deep Bio develops and sells AI-powered digital pathology software (the DeepDx suite) that analyzes whole-slide images of H&E-stained and IHC-stained tissue specimens to detect, grade, and quantify cancer. The software targets prostate cancer (core needle biopsy, radical prostatectomy, TURP specimens) and breast cancer (resection, sentinel lymph node biopsy), and is licensed to hospitals, pathology labs, and integrated into major digital pathology platforms including Roche navify, PathAI AISight, Visiopharm, Indica Labs HALO AP, Gestalt PathFlow, and Tribun Health CaloPix.

Is Deep Bio a public or private company?

Deep Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Deep Bio founded?

Deep Bio was founded in 2015. It employs 11 to 50 people.

Where is Deep Bio based?

Deep Bio is headquartered in Seoul, South Korea, in the Asia region.

How does Deep Bio make money?

Three revenue lines are on record. AI Diagnostic Software Licensing is the primary driver. The others are enterprise Software Sales and platform Integration Licensing.

Who are Deep Bio's main competitors?

Direct peers on record are AIRA Matrix, Paige.AI, Ibex Medical Analytics, PathAI, Owkin and Proscia. Lunit is listed as a regional player. Broad incumbents are Roche (navify Digital Pathology) and Philips Digital Pathology. Visiopharm is listed as an others.

Does Deep Bio have an API?

No public API is recorded for Deep Bio.

What industry is Deep Bio in?

Deep Bio's product category is Digital Pathology AI Diagnostics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
KBRDeep Bio trims headcount and leans on Roche, PathAI to speed US prostate pathology salesDeep Bio, a Korean AI company focused on quantifying prostate cancer from digitized biopsy slides, has cut its headcount to nine employees from about 30 and is now relying on distribution partnerships with large digital pathology platform vendors including Roche Diagnostics and PathAI to penetrate the U.S. hospital market. The company is simultaneously working to close a financing round of approximately 3.5 billion won ($2.4 million), with one U.S. hospital deal moving through contracting and another selected verbally. Deep Bio's strategy leverages existing platform master agreements to bypass the longer legal review process that hospitals often require when contracting directly with foreign vendors.KBR[Exclusive] Deep Bio staff exodus throws Roche, PathAI ties into doubtDeep Bio, a Seoul-based digital pathology AI startup, has experienced a near-total staff exodus with headcount falling from 35 employees in May 2024 to approximately 13 by October 2025 and an annual turnover rate of 92 percent, leaving only three senior executives reportedly remaining. The collapse raises urgent questions about the company's ability to maintain its software, support ongoing deployments, and fulfill active partnership obligations with Roche Diagnostics and PathAI for its prostate cancer diagnosis tool. The unraveling comes as Deep Bio had been planning overseas sales, a U.S. market entry including a potential CLIA-certified lab acquisition, and an IPO push, all of which now face existential uncertainty.EIN PresswireDeep Bio’s AI Predicts Breast Cancer Recurrence Risk from Standard Pathology SlidesDeep Bio Inc. announced publication of a peer-reviewed study in Nature Scientific Reports demonstrating that its deep learning AI model can predict breast cancer recurrence risk from standard H&E-stained pathology slides with 87.75% concordance with the Oncotype DX 21-gene assay. The study, conducted in collaboration with Korea University Guro Hospital and the National Cancer Center on 125 early-stage breast cancer cases, achieved 91.2% accuracy in identifying high-risk cases by learning molecular-level features from tissue morphology. The company positions this as a potential alternative to costly genomic testing, enabling more affordable and scalable precision oncology.PaigePathAI Announces Integrations with Leading AI-pathology companies Deep Bio, DoMore Diagnostics, Paige, and Visiopharm, through its AISight Image Management System — Paige.aiPathAI announced the integration of several AI products from digital pathology companies Deep Bio, DoMore Diagnostics, Paige, and Visiopharm into its AISight Image Management System in Boston, MA on November 19, 2024. These collaborations aim to enhance diagnostics and improve patient care by providing access to advanced algorithms and streamlining pathology workflows. The integrations signal PathAI's commitment to interoperability and advancing digital pathology solutions.YahooPathAI Announces Integrations with Leading AI-pathology Companies Deep Bio, DoMore Diagnostics, Paige, and Visiopharm, through its AISight Image Management SystemPathAI announced integrations of AI products from Deep Bio, DoMore Diagnostics, Paige, and Visiopharm into its AISight Image Management System. The collaborations bring algorithms from these companies directly into the platform, aiming to enhance interoperability and workflow efficiency for pathologists.DeepbioDeep Bio and PathAI Collaborate to Drive AI-Powered Innovations in Digital Pathology – Deep BioDeep Bio and PathAI announced a collaboration to integrate DeepDx Prostate, a CE-marked AI prostate cancer analysis tool, into PathAI's AISight image management system. The integration expands access to the AI diagnostic across North America and Europe, aiming to improve prostate cancer diagnostics and treatment planning.PathaiPathAI Announces Integrations with Leading AI-pathology companies Deep Bio, DoMore Diagnostics, Paige, and Visiopharm, through its AISight Image Management SystemPathAI announced the integration of AI pathology algorithms from Deep Bio, DoMore Diagnostics, Paige, and Visiopharm into its AISight Image Management System. This collaboration allows partner laboratories to access a diverse portfolio of digital pathology solutions directly within the PathAI platform, aiming to streamline workflows and improve diagnostic accuracy. The move reinforces PathAI's commitment to building a robust ecosystem of interoperable AI tools for the digital pathology market.ChosunbizGlobal interest grows in Korean medical AI ahead of US FDA green lightKorean medical AI companies are gaining global interest as their software reduces doctors' workloads and improves diagnostics. Lunit and Deep Bio are supplying AI to Roche Diagnostics, with more FDA approvals expected by mid-2024. The U.S. market is a key focus, with stroke and cardiac AI tools seeking approval.DeepbioDeep Bio Unveils Research Findings on Performance Evaluation of AI Algorithm for Breast Cancer Analysis – Deep BioDeep Bio published a study evaluating its AI algorithm for differentiating invasive ductal carcinoma from ductal carcinoma in situ in breast biopsies. The Multi-resolution Selective Segmentation Model achieved 96.88% pixel-level accuracy on H&E slides, outperforming existing models. The company plans to further innovate with AI solutions for breast cancer analysis.DeepbioDeep Bio to Present Research Findings at Poster Sessions during AACR Annual Meeting 2024 – Deep BioDeep Bio will present three research posters at the AACR Annual Meeting 2024 in San Diego, covering AI-driven pathology. The posters include semi-automated Ki-67 assessment, frozen section cancer discrimination, and morphological differences in BRCA-mutated ovarian cancer. CEO Sun Woo Kim noted this is the third consecutive year of such presentations.